The role of selectins in alopecia areata

Wiesława Sudnik¹, Aleksandra Dańczak-Pazdrowska¹, Wojciech Silny², Agnieszka Osmola-Mańkowska¹, Jakub Pazdrowski³, Adriana Polańska⁴

¹Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
Head of Department: Zygmunt Adamski MD, PhD
²Great Poland Center of Allergology and Aesthetic Dermatology “Art Clinic”, Poznan, Poland
Head of Center: Prof. Wojciech Silny MD, PhD
³Department of Head and Neck Surgery, Poznan University of Medical Sciences, Poznan, Poland
Head of Department: Wojciech Golusiński MD, PhD
⁴Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznan, Poland
Head of Department: Ryszard Żaba MD, PhD

Postep Derm Alergol 2015; XXXII, 1: 27–32
DOI: 10.5114/pdia.2014.40946

Abstract

Introduction: One of the main histopathological features of alopecia areata (AA) is a lymphocytic infiltration that surrounds hair follicles. Soluble forms of E, L, P-selectins are known indicators of ongoing inflammation. There are no studies regarding the assessment of their contribution in AA.

Aim: To assess serum concentrations of selectins (E-selectin, L-selectin and P-selectin) in patients with AA in relation to selected clinical parameters, including disease severity and activity.

Material and methods: Sixty-four patients with AA were involved in the study. The diagnosis was based on physical examination and photodermoscopy. The control group consisted of 40 healthy subjects. The serum concentrations of soluble E-selectin, L-selectin and P-selectin were detected with ELISA method.

Results: Statistically significantly higher levels of E, P, L-selectins were found in AA patients as compared with the healthy group. Serum concentrations of soluble forms of E- and L-selectins correlated with the severity of the disease, while E-selectin with activity of AA.

Conclusions: This study shows that selectins may play an important role in the pathogenesis of AA and may be a target of future therapies in this disease.

Key words: alopecia areata, E-selectin, P-selectin, L-selectin.

Introduction

Alopecia areata (AA) is a reversible, immunologically mediated syndrome, causing the destruction of hair follicles and subsequent immediate hair loss. The disease has usually long-term duration and because of its chronic nature significantly reduces the patient’s quality of life. Etiology and pathogenesis of the disease has not been fully elucidated. It has been suggested that damage to the hair follicle occurs in connection with the surrounding lymphocytic infiltration, which was observed in histopathologic examination [1, 2]. Another pathogenetic factor is associated with impaired angiogenesis [1–3] with a crucial contribution of selectins. E-selectin is considered as one of the major markers of endothelial cell damage, while soluble forms of E-selectin, L-selectin and P-selectin are considered as indicators of ongoing inflammation [2].

Significance of selectins was mainly assessed in psoriasis, but their abnormal serum concentration have also been demonstrated in systemic lupus erythematosus, scleroderma, urticaria, eczema, lichen planus, bullous pemphigoid, pemphigus vulgaris, graft versus host disease [4–22]. There are still no studies regarding the assessment of serum concentrations of soluble E-selectin, L-selectin and P-selectin forms in patients with AA.

Aim

Therefore, the main objective of this study was to assess serum concentrations of selectins (E-selectin,
L-selectin and P-selectin) in patients with AA in relation to the control group. Additionally, the analysis of correlations between selectins (E-selectin, L-selectin and P-selectin) and selected clinical parameters, including the severity of the disease and its activity were evaluated.

Material and methods

Sixty-four patients with AA were involved in the study. There were 67.2% of women (43 patients) and 32.8% of men (21 patients). The average age of patients was 31.8 ±15.9 years. 62.5% of patients presented AA circumscribed (AAC), while 37.5% were diagnosed with alopecia totalis and alopecia universalis (AT/AU, respectively). The characteristics of the entire study group are presented in Table 1.

The diagnosis of AA was made on the basis of physical examination and photodermoscopy [23–25].

The patients with co-morbidities other than autoimmune diseases associated with AA, as well as patients receiving systemic treatment in the last 6 months (e.g. corticosteroids, phototherapy, cyclosporine A) were excluded from the study. In addition, patients treated in the last 6 months with antihistamines or vascular drugs (e.g. vitamin K antagonists, heparin, aspirin, ticlopidine, clopidogrel, pentoxifylline, diosmin) due to their ability to affect the concentration of soluble forms of selectins [26] were also not enrolled to the study.

The control group consisted of 40 healthy subjects. There were 67.2% of women (43 patients) and 32.8% of men (21 patients). The average age in this group was 32.8 ±8.2 years.

In evaluation of disease activity the 3 months’ time was taken into consideration. According to Olsen, the disease is active when in the last 3 months a new area of hair loss appeared, or the expansion of the existing ones is observed [23, 27].

Material and methods

The diagnosis of AA was made on the basis of physical examination and photodermoscopy [23–25].

The patients with co-morbidities other than autoimmune diseases associated with AA, as well as patients receiving systemic treatment in the last 6 months (e.g. corticosteroids, phototherapy, cyclosporine A) were excluded from the study. In addition, patients treated in the last 6 months with antihistamines or vascular drugs (e.g. vitamin K antagonists, heparin, aspirin, ticlopidine, clopidogrel, pentoxifylline, diosmin) due to their ability to affect the concentration of soluble forms of selectins [26] were also not enrolled to the study.

The control group consisted of 40 healthy subjects. There were 67.2% of women (43 patients) and 32.8% of men (21 patients). The average age in this group was 32.8 ±8.2 years.

In physical examination, the number, extent and localization of the hair loss areas were evaluated with a detailed observation of the skin in close vicinity to affected regions. Dermoscopy was performed using photodermoscope Heine Delta 20 (Germany) and dermoscopic evaluation included assessment of features described in the literature [24].

In evaluation of disease activity the 3 months’ time was taken into consideration. According to Olsen, the disease is active when in the last 3 months a new area of hair loss appeared, or the expansion of the existing ones is observed [23, 27].

The serum concentrations of soluble E-selectin, L-selectin and P-selectin were detected with ELISA method using kits R&D Systems (Minneapolis, USA): Quantikine Human sE Immunoassay kit (R&D, USA), Quantikine Human sL Immunoassay kit (R&D, USA) sP and Quantikine Human Immunoassay kit (R&D, USA). Tests were performed in accordance with the methodology provided by the manufacturer. Measurements were performed with spectrophotometer EPOCH (Biokom).

Statistical analysis

The analyzed parameters such as measurable concentrations of selectins, age of the patients were described as arithmetic mean and standard deviation. Concordance between these parameters with a normal distribution was assessed with the Shapiro-Wilk test. The comparison between groups was made with t-Student test for independent variables. The homogeneity of variance was tested by Leven or Welch’s test if variances were heterogeneous. When there was no evidence of compliance with the normal distribution, nonparametric Mann-Whitney test was used. The accepted level of significance was p ≤ 0.05. The calculations were based on a statistical package Statistica (data analysis software system), v9 and Analyse, Microsoft Excel v2.20.

Results

The average concentration of the soluble form of E-selectin in AA patients was 39.1 ±17.5 ng/ml. The average concentration of E-selectin taking into account the severity of the disease was 33.5 ±13.9 in AAC group, whereas in AT/AU it was 48.3 ±19.1 ng/ml. In the healthy control group, the mean concentration of E-selectin was 27.7 ±12.1 ng/ml. The average serum level of the soluble form of E-selectin in patients with active AA phase was 48.0 ±17.5 ng/ml, whereas in the inactive phase it was 31.2 ±13.4 ng/ml. Statistically significantly higher levels of E-selectin were found in the AA group as compared with the healthy group (p = 0.0003) and in the group of patients with AAC (p = 0.0327) and AT/AU (p = 0.0001). There was a statistically significant difference in concentration of the soluble form of E-selectin between AAC and AT/AU patients (p = 0.0011). Statistically significantly higher concentrations of the soluble forms of E-selectin in the serum of patients with AA were observed in the active phase of disease in comparison to patients with inactive state (p < 0.0001).

The average concentration of the soluble form of L-selectin in the serum of all AA group was 1676.9 ±624.1 ng/ml (Table 1). The average concentration of L-selectin in regards of disease severity for AAC was 1488.8 ±426.1 ng/ml, whereas for AT/AU it was 1990.3 ±771.3 ng/ml. In the control group, the mean concentration of L-selectin was

### Table 1. Characteristics of patients with AA

| Parameter       | Result          |
|-----------------|-----------------|
| Number of patients, n (%) | 64 (100)        |
| Gender, n (%)    |                 |
| Female          | 43 (67.2)       |
| Male            | 21 (32.8)       |
| Age [years]     |                 |
| Mean ± SD       | 31.8 ±15.9      |
| Median          | 33              |
| Minimal value   | 3               |
| Maximal value   | 62              |

W. Sudnik, A. Dańczak-Pazdrowska, W. Silny, A. Osmola-Mańkowska, J. Pazdrowski, A. Polańska
The role of selectins in alopecia areata

Alopecia areata is a chronic disease mediated by T lymphocytes and despite numerous studies, its pathogenesis still has not been fully elucidated. The histological examination of AA patients’ skin reveals the large cell infiltration around the hair follicles with a high number of T cells and other inflammatory cells [28]. Their presence may lead to the release of cytokines within the hair follicle [29]. Cormia and Ernyey demonstrated within bald skin may lead to the release of cytokines within the hair follicle filtration around the hair follicles with a high number of inflammatory infiltrate also around blood vessels with a thickening of their walls [30]. Another interesting pathogenetic issue is related to elevated serum concentrations of selectins, which are known as first adhesion molecules involved in lymphocyte migration through the vessel wall and may reflect vascular abnormalities [31].

One of the molecules analyzed in this report was E-selectin that plays an important role in guiding T lymphocytes to the sites of inflammation [32–34]. This selectin also is a ligand of the antigens found on the surface of inflammatory cells, including cutaneous lymphocyte-associated antigen (CLA). To date, no study has been published assessing the concentration of E-selectin in the serum of patients with AA. Previous reports focused mainly on the clinical expression of E-selectin in the skin of patients with AA [35–38]. Toyoda et al. observed an increased expression of this molecule on perifollicular endothelial cells in skin samples obtained from the center of the AA areas [38]. Gheretich et al. in immunohistochemical studies also found an increased E-selectin expression, including the skin of the scalp not involved in the disease process (seemingly healthy skin), but only in the active phase of the disease [37]. This author suggests the existence of subclinical AA, which is characterized by no hair loss, but in immunohistochemistry by presence of numerous inflammatory cells around the blood vessels within seemingly healthy skin and spared perifollicular region [37]. Another author observed a high expression of E-selectin in a patient with 14 years’ history of AA, which was comparable to one observed in psoriatic skin [36].

In this study we noted a significantly higher serum level of soluble form of E-selectin in patients with AA (39.1 ±17.5 ng/ml) compared to healthy controls (27.7 ±12.1 ng/ml). It can therefore be assumed that its elevated level, most likely induced by scaling of the selectin from the surface of endothelial cells, may be indicative of an ongoing inflammatory process in the vessels [31]. We also detected a higher average concentration of E-selectin in patients with more severe AA what may be related to the severity of lymphocytic infiltration in various forms of AA. Dy and Whiting reported a lower lymphocytes concentration in AAC and greater in AT/AU [39]. Additionally, we observed a statistically significant difference in concentration of the soluble form of E-selectin between active and inactive

| Analyzed populations | Value of \( p \) |
|----------------------|-----------------|
| AA/healthy           | 0.0003* 0.0026* 0.0275* |
| AAC/healthy          | 0.0327* 0.0543 0.0153* |
| AT AU/healthy        | 0.0001* 0.0005* 0.1842 |
| AAC/AT/AU            | 0.0011* 0.0063* 0.2865 |
| AA active/AA inactive| < 0.0001* 0.1577 0.2670 |

*Statistically significant difference.
phase of the disease, with higher values observed in the former form. These results suggest that E-selectin plays a significant role in the development of disease and may be a marker of a more severe type of AA. In this context and given the difficulties in the treatment of AA, we should consider the possibility of initiation of treatment aimed at inhibiting the activity of selectins, including E-selectin.

Another analyzed adhesion molecule was L-selectin which is detected on the surface of lymphocytes, granulocytes and monocytes [40]. Its expression decreases after cell activation. The inflammatory mediators peel of L-selectin from leukocyte cell surface what leads to the increase its soluble forms [41, 42]. Soluble forms of this molecule are probably capable of inhibiting the adhesion processes [41]. Until now there have been no studies regarding serum concentrations of soluble form of L-selectins and its expression within skin of AA patients. In the present research we observed significantly higher levels of soluble form of L-selectin in the serum of patients with AA (1676.9 ±624.1 ng/ml) than in the control group (1424.6 ±765.8 ng/ml). Also, serum concentrations of soluble form of L-selectin was significantly higher in patients with AT/AU (1990.3 ±771.3 ng/ml) compared to patients with AAC (1488.8 ±426.1 ng/ml). We found no significant difference in the serum form of L-selectin is probably a component of the buffer system, which limits the process of rolling leukocytes and thus their migration to sites of inflammation [41, 42]. High concentrations of soluble L-selectins in patients with AA presented in our project can also limit the migration of leukocytes to sites of inflammation. It seems that evaluation of expression of this selectins in the skin of AA patients would be beneficial.

The third selectin evaluated in this project was P-selectin. This molecule is expressed within the surface of activated platelets and endothelial cells. The literature data indicate that there are many forms of soluble P-selectin, which originate predominantly from the exfoliation of the cell surface [43, 44]. Those serum forms are still functionally active and exhibit procoagulant activity being engaged in the development of vascular thrombosis [44]. Serum concentrations of soluble forms of E- and L-selectin correlated with the severity of the disease, while E-selectin with activity of AA. Significantly higher concentrations of all tested selectins observed in this study should be considered in regards of new therapeutic approaches aimed at blocking their activity. These drugs are now being tested with a good effect in clinical trials in the group of patients with psoriasis [46], what gives hope for their future use in patients with hair loss. What is more, we found that selectins serum levels in analyzed AA population were higher than observed in our psoriatic patients (our unpublished data) and that makes such anti-selectin therapy especially useful.

Conclusions
This study shows that selectins may play an important role in the pathogenesis of AA, especially E and L ones. Serum concentrations of soluble forms of E- and L-selectin correlated with the severity of the disease, while E-selectin with activity of AA. Significantly higher concentrations of all tested selectins observed in this study should be considered in regards of new therapeutic approaches aimed at blocking their activity. These drugs are now being tested with a good effect in clinical trials in the group of patients with psoriasis [46], what gives hope for their future use in patients with hair loss. What is more, we found that selectins serum levels in analyzed AA population were higher than observed in our psoriatic patients (our unpublished data) and that makes such anti-selectin therapy especially useful.

Conflict of interest
The authors declare no conflict of interest.

References
1. Lever WF. Histopathology of the skin. Gundula Scharnb-urg-Lewer 1990; 223-4.
2. Wang E, McElwee KJ. Etiopathogenesis of alopecia areata: why do our patients get it? Dermatol Ther 2011; 24: 337-47.
3. Popchristov P, Konstantinov A, Obreshkova E. The blood ves-sels of the scalp in patients with alopecia areata before and after corticosteroid therapy. Br J Derm 1968; 80: 753-7.
4. Groves RW, Kapahi P, Barker JN, et al. Detection of circulat-ing adhesion molecules in erythrodermic skin disease. J Am Acad Dermatol 1995; 32: 32-6.
22. Ciołkiewicz M, Kuryliszyn-Moskal A, Klimiuk PA. Analysis of

21. Olewicz-Gawlik A, Danczak-Pazdrowska A, Klama K, et al.

19. Olewicz-Gawlik A, Danczak-Pazdrowska A, Klama K, et al.

18. Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, et al.

17. Caproni M, Volpi W, Giomi B, et al.

16. Borska L, Fiala Z, Krejsek J, et al.

14. Lis-Święty A, Rogala-Poborska I, Syguła E.

13. Yano S, Nakamura K, Tamaki K.

12. Furue M, Koga T, Yamashita N.

11. Kitamura T, Tamada Y, Kato M, et al.

10. Ihm CW, Han JH.

9. Yamamoto T, Matsuuchi M, Watanabe K, et al.

8. Yamamoto T, Matsuuchi M, Watanabe K, et al.

7. Carmona C, Pineyro I, Martinez M, et al.

6. Morita H, Kitano Y, Kawasaki N.

5. Morita H, Kitano Y, Kawasaki N.

4. Kamińska-Winciorek G.

3. Team T, Tamada Y, Kato M, et al.

2. Yamasaki Y, Ishii K, Kato M, et al.

1. Itoh H, Suzuki H, Iwai T, et al.
44. Beeh KM, Beier J, Meyer M, et al. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over trial. Pulm Pharmacol Ther 2006; 19: 233-41.
45. Dymicka-Piekarska V, Matowicka-Karna J, Osada J. Changes in platelet CD 62P expression and soluble P-selectin concentration in surgically treated colorectal carcinoma. Adv Med Sci 2006; 51: 304-8.
46. Erhardt C, Kneuer C, Bakowsky U. Selectins–an emerging target for drug delivery. Adv Drug Delivery Rev 2004; 56: 527-49.